172 related articles for article (PubMed ID: 8222520)
1. Atovaquone: a new antipneumocystis agent.
Artymowicz RJ; James VE
Clin Pharm; 1993 Aug; 12(8):563-70. PubMed ID: 8222520
[TBL] [Abstract][Full Text] [Related]
2. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration.
Cotton D
AIDS Clin Care; 1995 Jul; 7(7):62. PubMed ID: 11362554
[TBL] [Abstract][Full Text] [Related]
4. FDA approves new PCP drug. Food and Drug Administration.
AIDS Alert; 1995 Aug; 10(8):108. PubMed ID: 11362680
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
Deresinski SC
Semin Respir Infect; 1997 Jun; 12(2):79-97. PubMed ID: 9195673
[TBL] [Abstract][Full Text] [Related]
6. Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Castro M
Semin Respir Infect; 1998 Dec; 13(4):296-303. PubMed ID: 9872626
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study.
Meyers B; Borrego F; Papanicolaou G
Liver Transpl; 2001 Aug; 7(8):750-1. PubMed ID: 11510024
[TBL] [Abstract][Full Text] [Related]
8. Optimizing PCP therapy.
Torres G; Cadman J
GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
10. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.
Chan C; Montaner J; Lefebvre EA; Morey G; Dohn M; McIvor RA; Scott J; Marina R; Caldwell P
J Infect Dis; 1999 Aug; 180(2):369-76. PubMed ID: 10395851
[TBL] [Abstract][Full Text] [Related]
11. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
Hughes WT
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
[TBL] [Abstract][Full Text] [Related]
12. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
Spencer CM; Goa KL
Drugs; 1995 Jul; 50(1):176-96. PubMed ID: 7588086
[TBL] [Abstract][Full Text] [Related]
13. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia.
Drake S; Lampasona V; Nicks HL; Schwarzmann SW
Clin Pharm; 1985; 4(5):507-16. PubMed ID: 3902329
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment and prophylaxis of Pneumocystis carinii pneumonia.
Warren E; George S; You J; Kazanjian P
Pharmacotherapy; 1997; 17(5):900-16. PubMed ID: 9324180
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with atovaquone on a treatment investigational new drug protocol for Pneumocystis carinii pneumonia.
White A; LaFon S; Rogers M; Andrews E; Brown N
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):280-5. PubMed ID: 7788426
[TBL] [Abstract][Full Text] [Related]
16. Atovaquone: a review.
Haile LG; Flaherty JF
Ann Pharmacother; 1993 Dec; 27(12):1488-94. PubMed ID: 8305784
[TBL] [Abstract][Full Text] [Related]
17. Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.
Zarkin GA; Bala MV; Wood LL; Bennett CL; Simpson K; Dohn MN
Pharmacoeconomics; 1996 Jun; 9(6):525-34. PubMed ID: 10160480
[TBL] [Abstract][Full Text] [Related]
18. [New aspects of epidemiology and treatment of Pneumocystis carinii infection].
Powierska-Czarny J; Gospodarek E; Czerwionka-Szaflarska M
Pol Merkur Lekarski; 2004 Nov; 17(101):534-7. PubMed ID: 15754652
[TBL] [Abstract][Full Text] [Related]
19. Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients.
Dohn MN; Frame PT; Baughman RP; Lafon SW; Smulian AG; Caldwell P; Rogers MD
J Protozool; 1991; 38(6):220S-221S. PubMed ID: 1818178
[TBL] [Abstract][Full Text] [Related]
20. Atovaquone for Pneumocystis carinii pneumonia.
Med Lett Drugs Ther; 1993 Apr; 35(893):28-9. PubMed ID: 8450807
[No Abstract] [Full Text] [Related]
[Next] [New Search]
